Brought to you by 
Quest Diagnostics to co-promote Cytyc's ThinPrep Pap Test
07 May 2003
Executive Summary
Cytyc and Quest Diagnostics (provider of clinical testing information and services) will combine sales and marketing resources to promote Cytyc's ThinPrep Pap Test--a screen for cervical cancer--to payers, physicians, and patients in the US. In exchange, Quest will receive a warrant to purchase 150,000 shares of Cytyc common stock at $61 per share, for a $915,000 equity investment.
Deal Industry
- Biotechnology
- Laboratory Testing Services
-
In Vitro Diagnostics
- Cytology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Quest Diagnostics to co-promote Cytyc's ThinPrep Pap Test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice